NVIDIA has announced new partnerships to transform the USD 10 trillion healthcare and life sciences industry by accelerating drug discovery, enhancing genomic research and pioneering advanced healthcare services with agentic and generative AI.

The convergence of AI, accelerated computing and biological data is turning healthcare into the largest technology industry. Healthcare leaders IQVIA, Illumina and Mayo Clinic, as well as Arc Institute, are using the latest NVIDIA technologies to develop solutions that will help advance human health.

These solutions include AI agents that can speed clinical trials by reducing administrative burden, AI models that learn from biology instruments to advance drug discovery and digital pathology, and physical AI robots for surgery, patient monitoring and operations. AI agents, AI instruments and AI robots will help address the USD 3 trillion of operations dedicated to supporting industry growth and create an AI factory opportunity in the hundreds of billions of dollars.

“AI offers an exceptional opportunity to advance healthcare and life sciences with tools that help providers detect diseases earlier and discover new treatments faster. The combination of NVIDIA’s AI and accelerated computing capabilities with the expertise of industry leaders is poised to usher in a new era of medical and biological innovation and improve patient outcomes worldwide,” said Kimberly Powell, Vice President of Healthcare at NVIDIA.

IQVIA uses the NVIDIA AI Foundry service to build custom foundation models on its more than 64 petabytes of information, coupled with its deep domain expertise. The company is also developing agentic AI solutions, outfitted with NVIDIA AI Enterprise software including NVIDIA NIM™ microservices and NVIDIA Blueprints, that can speed research, clinical development and access to new treatments. IQVIA has been leading in the responsible use of AI, ensuring that its AI-powered capabilities are grounded in privacy, regulatory compliance and patient safety.

“This represents a significant leap forward in how we apply AI to healthcare and life sciences. We are excited to combine our industry-leading capabilities and a decade of experience in artificial intelligence with NVIDIA’s advanced AI technologies to build new solutions powered by AI agents that are trained on world-class healthcare information and optimized for life sciences workflows. This collaboration will advance our mission to help our clients accelerate innovation and treatments to market,” said Bhavik Patel, President of Commercial Solutions at IQVIA.

Illumina, a global leader in DNA sequencing and informatics technologies, is working with NVIDIA to unlock the next generation of genomics for drug discovery and human health.

This partnership will enable Illumina to use NVIDIA accelerated computing and AI toolsets for its multiomics analysis software and workflows. This will help make analysis of — and insights from — the human genome more accessible to researchers, pharmaceutical companies and other life sciences customers.

Illumina will offer DRAGEN analysis software on NVIDIA accelerated computing within the Illumina Connected Analytics platform. The integration aims to expand DRAGEN accessibility globally to wherever NVIDIA’s computing platform exists.

Over the last five years, single-cell and spatial genomics have revolutionized drug discovery by providing unprecedented insights into cell understanding. To further expand the genomics market and help enable breakthroughs in target identification, clinical development and biomarker discovery, NVIDIA and Illumina plan to collaborate to progress multiomics data analysis on the Illumina Connected Analytics platform, in addition to developing new biology foundation models.

The R&D community can more quickly and easily tap into rich genomic data by integrating NVIDIA RAPIDS™ accelerated data science software, included in the NVIDIA AI Enterprise software platform, with the NVIDIA BioNeMo platform’s generative AI models and fine-tuning capabilities for proprietary datasets, and MONAI for spatial cell imaging workflows. Illumina and NVIDIA will work to make these tools accessible on the Illumina Connected Analytics platform.

“Our ability to combine the power of AI with multiomics data is revolutionizing how we can understand disease. By combining Illumina’s expertise in genomics data and analysis with NVIDIA’s powerful AI platforms, we aim to enable pharma and biotech companies to unlock their own multiomics data to uncover transformative insights and improve success rates in developing lifesaving therapies,” said Steve Barnard, chief technology officer at Illumina.